Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
Ayalew Tefferi, Terra L. Lasho, Omar Abdel‐Wahab, et al.
Leukemia (2010) Vol. 24, Iss. 7, pp. 1302-1309
Open Access | Times Cited: 310

Showing 1-25 of 310 citing articles:

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
María E. Figueroa, Omar Abdel‐Wahab, Chao Lü, et al.
Cancer Cell (2010) Vol. 18, Iss. 6, pp. 553-567
Open Access | Times Cited: 2601
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat, Domenica Caramazza, Rakhee Vaidya, et al.
Journal of Clinical Oncology (2010) Vol. 29, Iss. 4, pp. 392-397
Open Access | Times Cited: 977
Metabolic requirements for the maintenance of self-renewing stem cells
Keisuke Ito, Toshio Suda
Nature Reviews Molecular Cell Biology (2014) Vol. 15, Iss. 4, pp. 243-256
Open Access | Times Cited: 940
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih, Omar Abdel‐Wahab, Jay P. Patel, et al.
Nature reviews. Cancer (2012) Vol. 12, Iss. 9, pp. 599-612
Closed Access | Times Cited: 650
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker, Róbert Královics
Blood (2016) Vol. 129, Iss. 6, pp. 667-679
Open Access | Times Cited: 531
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman, William G. Kaelin
Genes & Development (2013) Vol. 27, Iss. 8, pp. 836-852
Open Access | Times Cited: 530
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Supriya K. Saha, Christine A. Parachoniak, Krishna S. Ghanta, et al.
Nature (2014) Vol. 513, Iss. 7516, pp. 110-114
Open Access | Times Cited: 404
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani, Jason Gotlib, Catriona Jamieson, et al.
Journal of Clinical Oncology (2011) Vol. 29, Iss. 7, pp. 789-796
Open Access | Times Cited: 397
IDH1andIDH2Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Hui Yang, Dan Ye, Kun‐Liang Guan, et al.
Clinical Cancer Research (2012) Vol. 18, Iss. 20, pp. 5562-5571
Open Access | Times Cited: 394
IDH mutations in glioma and acute myeloid leukemia
Lenny Dang, Shengfang Jin, Shinsan M. Su
Trends in Molecular Medicine (2010) Vol. 16, Iss. 9, pp. 387-397
Closed Access | Times Cited: 354
The future of epigenetic therapy in solid tumours—lessons from the past
Nilofer S. Azad, Cynthia A. Zahnow, Charles M. Rudin, et al.
Nature Reviews Clinical Oncology (2013) Vol. 10, Iss. 5, pp. 256-266
Open Access | Times Cited: 321
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi, William Vainchenker
Journal of Clinical Oncology (2011) Vol. 29, Iss. 5, pp. 573-582
Closed Access | Times Cited: 318
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Rafael Bejar, Ross L. Levine, Benjamin L. Ebert
Journal of Clinical Oncology (2011) Vol. 29, Iss. 5, pp. 504-515
Open Access | Times Cited: 306
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
Wen‐Chien Chou, Sheng‐Chieh Chou, Chieh‐Yu Liu, et al.
Blood (2011) Vol. 118, Iss. 14, pp. 3803-3810
Open Access | Times Cited: 304
Myeloproliferative Neoplasms
Ayalew Tefferi, Animesh Pardanani
JAMA Oncology (2015) Vol. 1, Iss. 1, pp. 97-97
Closed Access | Times Cited: 295
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Jorge E. Cortés, et al.
Nature Reviews Drug Discovery (2011) Vol. 10, Iss. 2, pp. 127-140
Closed Access | Times Cited: 284
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases
Éric Solary, Olivier Bernard, Ayalew Tefferi, et al.
Leukemia (2013) Vol. 28, Iss. 3, pp. 485-496
Open Access | Times Cited: 256
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
Annie Im, Alison R. Sehgal, Martin Carroll, et al.
Leukemia (2014) Vol. 28, Iss. 9, pp. 1774-1783
Open Access | Times Cited: 251
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2015) Vol. 90, Iss. 2, pp. 162-173
Closed Access | Times Cited: 242
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Benjamin R. Kipp, Jesse S. Voss, Sarah E. Kerr, et al.
Human Pathology (2012) Vol. 43, Iss. 10, pp. 1552-1558
Closed Access | Times Cited: 235
Targeting Epigenetics in Cancer
Richard L. Bennett, Jonathan D. Licht
The Annual Review of Pharmacology and Toxicology (2017) Vol. 58, Iss. 1, pp. 187-207
Open Access | Times Cited: 223
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
Sonia Cerquozzi, Ayalew Tefferi
Blood Cancer Journal (2015) Vol. 5, Iss. 11, pp. e366-e366
Open Access | Times Cited: 221
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi, Terra L. Lasho, Thitina Jimma, et al.
Mayo Clinic Proceedings (2012) Vol. 87, Iss. 1, pp. 25-33
Open Access | Times Cited: 218
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
Ayalew Tefferi, J. Thiele, Alessandro M. Vannucchi, et al.
Leukemia (2014) Vol. 28, Iss. 7, pp. 1407-1413
Open Access | Times Cited: 214
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
Mrinal M. Patnaik, Terra L. Lasho, Janice M. Hodnefield, et al.
Blood (2011) Vol. 119, Iss. 2, pp. 569-572
Open Access | Times Cited: 205
Page 1 - Next Page

Scroll to top